Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$129.50 USD

129.50
949,473

+1.81 (1.42%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $129.00 -0.50 (-0.39%) 5:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (58 out of 244)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Best Growth Stocks to Buy for November 16th

by Zacks Equity Research

MDV, LZ and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 16, 2023.

Zacks Equity Research

Encompass Health (EHC) Opens Hospital to Boost Presence in Texas

by Zacks Equity Research

Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.

Zacks Equity Research

Avantor's (AVTR) New Offerings to Aid Cell and Gene Therapy Suite

by Zacks Equity Research

Avantor's (AVTR) latest offerings are likely to provide its customers with products, materials and services that would aid in accelerating therapeutics.

Zacks Equity Research

Masimo's (MASI) Latest Tie-Up to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) latest joint effort is likely to enable real-time continuous monitoring with a tailored view of the patient's vitals while keeping them mobile during critical recovery periods.

Zacks Equity Research

All You Need to Know About DaVita HealthCare (DVA) Rating Upgrade to Strong Buy

by Zacks Equity Research

DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Veradigm's (MDRX) New Offering to Enhance Patient Engagement

by Zacks Equity Research

Veradigm's (MDRX) latest solution is likely to offer its clients the right payment option to each individual patient through the right communication channel.

Zacks Equity Research

Does DaVita HealthCare (DVA) Have the Potential to Rally 33.24% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 33.2% upside potential for DaVita HealthCare (DVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

DaVita's (DVA) robust segmental revenues drive its third-quarter performance.

Zacks Equity Research

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why DaVita HealthCare (DVA) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Are Investors Undervaluing DaVita (DVA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter.

Zacks Equity Research

NextGen (NXGN) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

NextGen's (NXGN) second-quarter fiscal 2024 results reflect strength in its Recurring revenues.

Zacks Equity Research

Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare

by Zacks Equity Research

Henry Schein (HSIC) completes the majority investment in Shield Healthcare, Inc.

Zacks Equity Research

DaVita's (DVA) Latest Partnership to Improve Kidney Care

by Zacks Equity Research

DaVita's (DVA) new tie-up is likely to enable it to harness Google Cloud's AI and analytics tools to improve care plans and streamline clinical workflows.

Zacks Equity Research

Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Zacks Equity Research

Is DaVita (DVA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes

by Zacks Equity Research

Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.

Zacks Equity Research

Align (ALGN) Gains From New Launches, Strategic Partnerships

by Zacks Equity Research

Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.

Zacks Equity Research

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.

Zacks Equity Research

Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Zacks Equity Research

PetMeds (PETS) to Advance Pet Care With New Collaboration

by Zacks Equity Research

PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.

Zacks Equity Research

Here's Why You Should Invest in Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.

Zacks Equity Research

Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?

by Zacks Equity Research

Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.

Zacks Equity Research

Teleflex (TFX) Advances Urology Portfolio With New Buyout

by Zacks Equity Research

Teleflex's (TFX) recent buyout is in line with its strategy of acquiring assets that accelerate the rate of expansion.